Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399505 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23291187 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23928138 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23291303 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23291174 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23928173 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23928106 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23928212 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23928108 | 0.96 | KMT2A (0.56) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17935564 | 0.86 | NPC1 (0.68) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | KMT2A 1530/4885MEN1 1329/4885RAB9A 2869/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | KMT2A 1530/4885MEN1 1329/4885RAB9A 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.